Navigation Links
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
Date:10/23/2008

NEW YORK and SAN DIEGO, Oct. 23, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Phenomix Corporation today announced that they have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. Dutogliptin is Phenomix' proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development in Type 2 diabetes mellitus.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Under the terms of the agreement, Forest will make an upfront payment to Phenomix of $75 million. Phenomix and Forest will jointly develop and commercialize dutogliptin in the United States, and the companies will equally share profits and expenses. Upon commercialization, the parties will co-promote the product in the United States, with Phenomix promoting dutogliptin to endocrinologists and diabetologists and Forest promoting to primary care and specialty physicians. Forest has exclusive rights to develop and commercialize dutogliptin in Canada and Mexico, and Phenomix will receive a royalty on sales in these countries in exchange for the rights to use jointly funded trial data in those countries. Phenomix retains development and commercialization rights to the product outside of North America, and will pay Forest a royalty on net sales in these territories. Phenomix could receive up to $340 million in upfront and milestone payments for the successful development and commercialization of dutogliptin in the United States over the term of the collaboration.

"Diabetes is a widespread and growing disease. We have
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
2. Oil palm plantations are no substitute for tropical rainforests, a new study shows
3. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
4. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
5. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
10. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
11. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... Texas Governor Rick Perry, Texas ... Health Science Center CEO Brett Giroir, M.D., and ... Human Services (HHS), State of Texas and biopharmaceutical ... vaccine manufacturing facility in Bryan, Texas, which when ... Texas A&M Biocorridor – a rapidly evolving hub ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts ... The global companion diagnostics market is expected to ... 2019. Factors such as rising need for personalized medicine ... the pharmaceutical industry, support from regulatory authorities, and emerging ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Inc., a clinical,stage biopharmaceutical company developing novel multi-component ... present at the,Wachovia 2008 Healthcare Conference in Boston, ... Among the topics of the presentation will ... developments, including Phase III development,activities related to its ...
... Jan. 28 Campbell Alliance, the leading,management consulting ... announced that Nader Naeymi-Rad, Senior,Vice President of the ... Oncology Summit Europe. The event will be held ... Hotel in London, England., Mr. Naeymi-Rad,s presentation, ...
... 28 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT.OB), ... disease, today announced the,appointment of Gregory W. Schafer ... the audit committee. Mr. Schafer is a seasoned ... biotechnology finance and operations., "We are delighted ...
Cached Biology Technology:Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit 2Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 2Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 3
(Date:9/19/2014)... The sense of fairness did not evolve for the ... reap the benefits of continued cooperation, so say Frans ... a review article about inequity aversion (IA), which is ... review is published in Science . , ... 35 IA-related studies to address their hypothesis that it ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... There are few things more irritating than a fly ... to the problem. They hang up a bunch of Roridula ... leaf,s hairs, the hapless pest is soon trapped by the ... story. Each R. gorgonias plant is home to a population ...
... model for studying the genetics of Angelman syndrome, a ... in one out of 15,000 births, has been developed ... Their research demonstrates that when a particular fruit ... behavioral dysfunctions similar to those experienced by humans whose ...
... Say the word "biofuels" and most people think of ... technology called gasification that,s getting a new look from ... and Iowa State University. By combining gasification with ... from a wide range of biomass, including distiller,s grain ...
Cached Biology News:Nothing stops an expert in the art of living 2Model for angelman syndrome developed by University of Texas at Austin biologists 2Turning waste material into ethanol 2
... LTQ XL extends the MSn performance of ... new tools to generate extensive structural information ... applications. , Multiple dissociation techniques (PQD, ... and unpredicted metabolites , Fast polarity switching ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
A substrate for all AChE-based EIA kits....
... secretion of cytoplasmic granules, is a ... of leukocytes (e.g. basophils, neutrophils, eosinophils, ... histamine, these secretory granules contain many ... and many proteases (Hallgren, 2001). Tryptase, ...
Biology Products: